Blue Lake Biotechnology Inc.

This study is testing a new nasal spray vaccine called BLB-201 to see if it is safe and can help protect infants and young children from Respiratory Syncytial Virus (RSV). The trial will enroll 137 healthy children aged 8 months to 5 years, some who have had RSV before and some w…